Edward Brent Perkins

Author

Virginia Commonwealth University

Also Known As

E. Brent Perkins, E. Perkins, E.Brent Perkins, Edward B. Perkins, Edward Brent Perkins, Edward Perkins

Publications

298

Citations

H-Index

Concepts

All Affiliations

Virginia Commonwealth University University of Pittsburgh Institute for Molecular Medicine Moffitt Cancer Center National Cancer Institute

About

Edward Brent Perkins is an author at Virginia Commonwealth University specializing in medicine, hematology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	87
2	Pathology	2	2	59
3	Health Sciences	1	1	40
4	Cell Biology	1	1	28
5	Pharmacology	1	1	19

Edward Brent Perkins

Publications

274

Citations

H-Index

Page 1

	Year	Citations
The Zinc Finger Repressor, ZBP-89, Binds to the Silencer Element of the Human Vimentin Gene and Complexes with the Transcriptional Activator, Sp1 Elżbieta Wieczorek, Zhili Lin, Edward Brent Perkins, Journal of Biological Chemistry	2000	68
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms Beata Holkova, Edward Brent Perkins, Viswanathan Ramakrishnan, Clinical Cancer Research	2011	48
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma Victor Yazbeck, Danielle Shafer, Edward Brent Perkins, Clinical Lymphoma Myeloma & Leukemia Hematological MalignancyLymphoid NeoplasiaPhase Ii TrialMantle Cell LymphomaMedicine	2018	40
A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 Beata Holkova, Jeffrey G. Supko, Matthew M. Ames, Clinical Cancer Research	2013	34
A GC-box is required for expression of the human vimentin gene Elena S. Izmailova, Elżbieta Wieczorek, Edward Brent Perkins, Gene Protein ExpressionGeneticsPathogenesisHuman Vimentin GeneGene Vector	1999	28
Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms Beata Holkova, Maciej Kmieciak, Edward Brent Perkins, Clinical Cancer Research	2014	26
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies Prithviraj Bose, Edward Brent Perkins, Connie Honeycut, Cancer Chemotherapy and Pharmacology Hematological MalignancyMedicineMalignant Blood DisorderHematologyPharmacology	2012	19
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma Beata Holkova, Edward Brent Perkins, Lubomir Sokol, Blood	2011	11

Page 1